ELOXX
Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many ... others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.
ELOXX
Industry:
Biotechnology Genetics Health Care
Founded:
2013-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.eloxxpharma.com
Total Employee:
11+
Status:
Active
Contact:
+1-781-577-5300
Email Addresses:
[email protected]
Total Funding:
92.39 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-04-01 | Zikani Therapeutics | Zikani Therapeutics acquired by Eloxx | N/A |
| 2017-06-03 | Sevion Therapeutics | Sevion Therapeutics acquired by Eloxx | N/A |
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Eloxx
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Eloxx
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Eloxx
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Eloxx
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Eloxx
Cybele Holdings
Cybele Holdings investment in Venture Round - Eloxx
Korea Investment Partners
Korea Investment Partners investment in Series C - Eloxx
Quark Venture
Quark Venture investment in Series C - Eloxx
Pontifax
Pontifax investment in Series C - Eloxx
LSP BioVentures
LSP BioVentures investment in Series C - Eloxx
Key Employee Changes
Official Site Inspections
http://www.eloxxpharma.com Semrush global rank: 9.48 M Semrush visits lastest month: 150
- Host name: 208.66.66.34.bc.googleusercontent.com
- IP address: 34.66.66.208
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
